Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsNVST -2.18%79 EV-to-EBITDA is 12.03 as of Aug. 06, 2026, which is 19% below its 10-year median of 14.85. GuruFocus rates NVST with a GF Score™ of 79/100 and a GF Value™ of $23.94 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Envista Holdings ranks better than 55.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Envista Holdings's enterprise value is $5,064 Mil.
Envista Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $421 Mil. Therefore, Envista Holdings's EV-to-EBITDA for today is 12.03.
The historical rank and industry rank for Envista Holdings's EV-to-EBITDA or its related term are showing as below:
NVST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.76 Med: 14.85 Max: 51.58
Current: 12.03
During the past 10 years, the highest EV-to-EBITDA of Envista Holdings was 51.58. The lowest was -4.76. And the median was 14.85.
NVST's EV-to-EBITDA is ranked better than 55.86% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.51
vs NVST: 12.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Envista Holdings's PE Ratio (TTM) for today is calculated as:
Envista Holdings's share price for today is $28.005.
Envista Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Envista Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Envista Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Envista Holdings's EV-to-EBITDA falls into.
Envista Holdings's current Enterprise Value is $5,064 Mil.
Envista Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $421 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envista Holdings (NVST) has a EV-to-EBITDA of 12.03 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Envista Holdings. This is 19% below median its historical median of 14.85. According to the industry distribution chart, Envista Holdings ranks #226 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 44.1%.
Is Envista Holdings' EV-to-EBITDA too high?
Envista Holdings' current EV-to-EBITDA of 12.03 is 19% below median its 10-year median of 14.85. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.51. Envista Holdings' value of 12.03 is 17.1% below this industry median. Based on the distribution chart, Envista Holdings ranks #226 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Envista Holdings has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' EV-to-EBITDA compare to MMSI and ICUI?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #226 out of 512 companies for EV-to-EBITDA. This puts Envista Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 14.51. Envista Holdings' value of 12.03 is 17.1% below this benchmark. While the company's 10-year median is 14.85 vs. the industry median of 14.51, Envista Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.51, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current EV-to-EBITDA of 12.03 is 17.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Envista Holdings. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current EV-to-EBITDA is 12.03, which is 19% below median its own 10-year median of 14.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Based on GuruFocus' analysis, Envista Holdings (NVST) is currently considered Modestly Overvalued. The stock's GF Value™ is $23.94, compared to a current price of $28.01 — trading 17% above its estimated fair value. The current EV-to-EBITDA is 12.03, which is 19% below median its 10-year median of 14.85 and 17.1% below the Medical Devices & Instruments industry median of 14.51. Envista Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Envista Holdings (NVST), the current EV-to-EBITDA is 12.03 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of $28.01 is trading 17% above its estimated GF Value™ of $23.94.
GuruFocus considers Envista Holdings to be Modestly Overvalued.
Key valuation signals for NVST:
EV-to-EBITDA: 12.03 (19% below median its 10-year median of 14.85)
GF Value™: $23.94 vs. price of $28.01 (17% above fair value)
Industry Position: 17.1% below the Medical Devices & Instruments median (#226 of 512)
No single metric tells the full story. See the NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
79GF Score
Get the complete analysis for NVST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVST has been successfully added to your 
